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Abstract
Pure seminoma is a rare pathology of the young adult, often discovered in the early stages. Its prognosis is
generally excellent and many therapeutic options are available, especially in stage I tumors. High cure rates can be
achieved in several ways: standard treatment with radiotherapy is challenged by surveillance and chemotherapy.
Toxicity issues and the patients’ preferences should be considered when management decisions are made. This
paper describes firstly the management of primary seminoma and its nodal involvement and, secondly, the various
therapeutic options according to stage.
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Testicular cancers, 95% of which are germ-cell tumors
(GCT), are the most common solid malignancies affect-
ing males between the ages of 15 and 35 years, although
it accounts for only about 1% of all cancers in men [1].
In 2010 it caused an estimated 350 deaths with 8480
new cases diagnosed in the United States alone [1]. In
Switzerland, and particularly in the Vaud canton, its
prevalence is one of the world’s highest, and is still
increasing [2]. Nevertheless its origin remains poorly
understood, although some environmental or genetic
risk factors are suspected [3]. It is also known to be
bilateral in 3% of cases [4]. GCT may consist of one pre-
dominant histologic pattern or represent a mixture of
multiple histologic types. For treatment purposes, two
broad categories are recognized: pure seminoma (no
nonseminomatous elements present), and all others,
which together are termed nonseminomatous germ-cell
tumors (NSGCT). Seminoma, 80% of which are diag-
nosed at stage I (Table 1), is highly sensitive to both
radiotherapy (RT) and chemotherapy (CHT) and, there-
fore, unlike many malignant neoplasms, cure is an
expected outcome in the majority of cases, even with
metastatic disease at presentation [3]. Its prognosis is
generally good, but the treatment-induced morbidity
must not be underestimated.
Diagnosis and surgical management
Testicular cancer commonly presents as a unilateral
lump or painless swelling noticed incidentally. Pain is
less common, with a third of patients presenting with a
dull ache, and acute pain is uncommon, occurring in
10% of patients at presentation. Testis cancers uncom-
monly present with symptoms related to metastatic dis-
ease [3]. The clinical examination may uncover a
testicular enlargement, and ultrasound examination con-
firms the existence of an intrascrotal tumor [5]. Pure
testicular seminomas do not have specific serum tumor
markers, but in certain cases can produce a small
amount of bHCG (b-subunit of human chorionic gona-
dotropin) [6].
High inguinal orchiectomy is the standard initial treat-
ment for suspected testicular carcinoma [7]. This strategy
allows accurate staging and histological diagnosis of the
tumor, while ensuring the best local control and minimiz-
ing treatment morbidity. Nonstandard surgical approaches
(scrotal violations), including scrotal orchiectomy, open
testicular biopsy and fine needle aspiration, have histori-
cally been condemned as significantly compromising prog-
nosis. Patients with scrotal violation are often subjected to
potentially morbid or disfiguring local therapies. In addi-
tion, patients with scrotal violations are usually disqualified
from surveillance protocols [8].
Several groups have proposed organ-sparing orchiect-
omy as an alternative option for a small group of
patients with bilateral testicular tumors, lesions in a soli-
tary testis, or metachronous contralateral tumors. This
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approach allows endocrinological, fertility, and psycholo-
gical advantages for the patient, especially in younger
men [4]. The German Testicular Cancer Intergroup and
others have reported prospective data on partial orch-
iectomy for GCT in a small subset of carefully selected
patients with a solitary testis or bilateral testicular
tumors [4]. Selection criteria in these studies included:
organ-confined disease with no infiltration of the rete-
testis; a mass of < 2 cm in order to preserve testoster-
one-producing parenchyma; a negative postresection
biopsy of the tumor bed; and conditions of cold ische-
mia to preserve the function of Sertoli and Leydig cells.
Heidenreich et al. have treated 73 patients with GCT
with partial orchiectomy using these criteria. Among
these, 17 were synchronous, 52 were metachronous and
4 occurred in a solitary testicle. After a median follow-
up of 91 months, 98.6% of patients had no evidence of
disease and one died of systemic tumor progression.
The presence of carcinoma in situ was described in
82.3% of patients. Eighty-five percent of all patients had
normal endogenous serum testosterone levels and did
not need exogenous androgen replacement [4].
Anatomic studies and detailed mapping studies of ret-
roperitoneal lymph node dissections have increased our
understanding of testicular lymphatic drainage and have
sharpened the focus of clinical staging and treatment by
identifying the most likely sites of metastatic disease.
The first echelon of lymph nodes draining the right tes-
tis is located in the inter-aortocaval region, followed by
the precaval and pre-aortic nodes [6]. Regarding left-
sided tumors, the first nodal stations include the pre-
aortic and para-aortic lymph nodes, left renal hilar
nodes followed by the inter-aortocaval nodes [6]. Con-
tralateral spread is common with right-sided tumors but
is rarely seen with left-sided tumors and is usually asso-
ciated with bulky disease [9]. More caudal deposits of
metastatic disease usually reflect retrograde spread to
distal iliac and inguinal lymph nodes secondary to a
large volume of disease and, more rarely, aberrant testi-
cular lymphatic drainage.
Table 1 Classification of seminomas according to UICC/AJCC and IGCCCG [7,61]
Clinical
Stage
TNM (UICC/AJCC) Category Blood tumor markers
(S)
T N M S LDH bHCG
(mIU/
ml)
AFP
(ng/
ml)
0 pTis carcinoma in situ N0 M0 - - - -
IA pT1 Limited to the testis and/or epididym, without lymphatic or
vascular invasion, the tumor can infiltrate the tunica albuginea but
not the tunical vaginalis
N0 M0 Any
S
level
Any
LDH
level
Any
bHCG
level
Norm.
IB pT2 Limited to the testis and/or epididym, without lymphatic or
vascular invasion, or spread through the tunica albuginea and
invasion of the tunica vaginalis
N0 M0 Any
S
level
Any
LDH
level
Any
bHCG
level
Norm.
pT3 Infiltration of the spermatic cord
pT4 Infiltration of the scrotal wall
IIA Any
T
stage
N1 (≤
2 cm)
M0 Any
S
level
Any
LDH
level
Any
bHCG
level
Norm.
IIB Any
T
stage
N1 (>
2 - 5
cm)
M0 Any
S
level
Any
LDH
level
Any
bHCG
level
Norm.
IIC Any
T
stage
N1 (>
5 cm)
M0 Any
S
level
Any
LDH
level
Any
bHCG
level
Norm.
IIIA/B/C Any
T
stage
Any N
stage
M1a (non-regional
nodes or lung
metastasis)
Any
S
level
Any
LDH
level
Any
bHCG
level
Norm.
IIIC Any
T
stage
Any N
stage
M1b (other
metastasis sites)
Any
S
level
Any
LDH
level
Any
bHCG
level
Norm.
IIIC Mediastinal primary tumor Any N
stage
Any M stage Any
S
level
Any
LDH
level
Any
bHCG
level
Norm.
LDH: lactate deshydrogenase, bHCG: Beta Human chorionic gonadotrophin, AFP: alpha-fetoprotein, T: tumor, N: nodes, M: metastasis, S:blood marker, AJCC:
American Joint Committee on Cancer, UICC: International Union Against Cancer, IGCCCG: International Germ Cell Cancer Collaborative Group
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Data comparing para-aortic nodal spread between
seminomatous and nonseminomatous testicular tumors
do not exist. From a theoretical point of view, we con-
sider that the primary zone of spread of testis tumors is
similar, and is not dependent on the histology [10]. In
all cases, those nodal areas are in close proximity to the
L1-L4 sympathetic roots of the superior hypogastric
plexus. When oncologically possible, they should be
spared at least unilaterally to preserve the ejaculation
function. This goes against the ancient dogma that
required a systematic and extended bilateral node dis-
section. Contrary to NSGCT, retroperitoneal lymph
node dissection (RPLND) is no longer regarded as a
valid therapeutic option in seminomas [11].
A good knowledge of the pathways of lymphatic nodal
spread is essential for the radiation oncologist in the
planning of the radiation treatment of the retroperito-
neal region.
Histology
Seminoma can be divided into three pathologic cate-
gories: classical, spermatocytic, and seminoma with syn-
cytiocytotrophoblastic cells. The spermatocytic type is
rare, occurs in older men, and may have a better prog-
nosis. The classical and the syncytiocytotrophoblastic
types of seminoma behave similarly, although the syncy-
tiocytotrophoblastic subtype is associated with increased
serum bhCG levels. Occasionally, seminoma may con-
tain numerous mitotic figures. When three or more
mitotic figures are identified per high power field
throughout the tumor, it is designated as seminoma
with high mitotic index or anaplastic seminoma.
Historically, anaplastic seminoma was thought to be a
more aggressive subtype of seminoma but subsequent
data failed to confirm this finding [12,13]. As an exam-
ple, in a retrospective analysis of prognostic factors for
relapse among 638 men with stage I seminoma, there
was only a trend towards worse five-year relapse-free
survival with anaplastic as compared to classical histol-
ogy (83 vs 71%, p = 0.056); in multivariate analysis, only
tumor size and rete-testis invasion were significant pre-
dictors of outcome [12]. Most seminomas are confined
to the testicle. Spread beyond the tunica into the sper-
matic cord occurs only in a minority of patients.
Stage I seminoma
Seminoma patients with clinical stage I (about 85% of all
stages) have a substantial risk of locoregional lymph
node micrometastases with a 20% risk of disease pro-
gression if no adjuvant therapy is administered after
orchiectomy. A primary tumor size of 4 cm or more
and invasion of the rete testis have been identified as
independent factors associated with an increased risk of
relapse in multivariate analysis in many retrospective
studies [11,12,14-16]. Some authors consider spread to
the rete-testis as a negative prognostic factor [12,14,16]
even it is not yet validated. The almost optimal cure
rate in these patients is close to 100%, regardless of
these features. This can be achieved with one of three
treatment options: surveillance with treatment only in
the case of relapse, adjuvant RT, or adjuvant single-
agent carboplatin CHT [11,17,18]. With a cause-specific
survival rate of 100%, the question is no longer ‘how
can the disease be cured?’ but rather ‘how can we retain
this excellent cure rate with the least risk of short- and
long-term consequences?’. Decisions regarding the man-
agement of stage I seminoma in any individual are thus
complex, and we need to take into account concerns
about long-term complications of RT and CHT, as well
as the patient’s ability to comply with intensive
surveillance.
Active surveillance
Surveillance policies offer the opportunity to detect
relapsing patients early whilst avoiding the morbidities
and risks of treatment for most [19]. No prospective
studies exist comparing surveillance alone versus adju-
vant treatment (RT or CHT). Several large prospective
nonrandomized studies of surveillance have been con-
ducted over the past 15 years. Reports have demon-
strated the feasibility of surveillance protocols,
particularly when associated with effective salvage regi-
mens [19]. Retrospective series from the Royal Marsden
Hospital London, from the Princess Margaret Hospital
(PMH), Toronto, and from a national collaboration in
Denmark, have all concluded that surveillance is a rea-
sonable policy, albeit with some practical difficulties in
view of the lack of sensitivity of specific serum markers
[15,20,21]. Consensus guidelines accept surveillance as
an option, which can be offered to stage I seminoma
patients following orchiectomy [11]. A recent paper
which analyses retrospectively a total of 649 patients
reports the evolution of treatment with an increased use
of active surveillance for stage I disease (545 patients)
without deaths related to seminoma [22]. The predomi-
nant site of relapse is in the para-aortic lymph nodes
and most patients are asymptomatic at the time of
detection. In the DATECA (Danish Testicular Carci-
noma Study Group) and in the PMH retrospective stu-
dies, 41 of 49 relapses (82%) and 54 of 67 relapses (89%)
occurred in the para-aortic lymph nodes, respectively.
Other sites of relapse included the pelvic lymph nodes
(approximately 3% overall), and very rarely the inguinal
nodes and the lungs [19,21].
Active surveillance permits avoiding development of a
second malignancy which is a concern for anyone
exposed to RT or CHT, especially in men with early
stage seminoma who are expected to survive for decades
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following treatment [23-25]. Data on the association of
infradiaphragmatic RT with subsequent cardiovascular
disease are conflicting [26,27]. The largest study to date
has included 40.576 testicular cancer survivors from 14
population-based tumor registries in Europe and North
America [23]. More than 7800 were followed for 20
years and 2065 for 30 years. An increased risk of second
solid cancers was seen among men treated with RT
alone (RR 2.0), CHT alone (RR 1.8), and with both mod-
alities (RR 2.9) [23,24]. Other rare complications may
happen, such as renal artery stenosis after RT [28].
The main drawback of surveillance is the need for
intensive follow-up and repeated imaging for at least 5
to 10 years after radical orchiectomy. Disadvantages
include expensive imaging tests, radiation exposure,
anxiety related to the risk of recurrence and the poten-
tial for patients to be noncompliant with follow-up
[29,30]. While there is a high rate of cure for patients
who experience recurrence and undergo definitive treat-
ment [19], they are likely to require combination CHT,
which has a greater toxicity risk than adjuvant treatment
with RT or single-dose carboplatin [25]. There is no
consensus regarding the optimum follow-up for these
patients [12]. Currently, patients at PMH are followed
up with regular physical examination, measurement of
serum tumor markers, and imaging for retroperitoneal
and chest disease. Patients are followed up at 4-monthly
intervals for the first 3 years, 6-monthly intervals in
years 4-7, and yearly intervals thereafter. At each visit, a
CT scan of the abdomen and pelvis is performed. Chest
x-rays are obtained at alternate visits. Serum tumor
marker levels are measured at each visit for the first 3
years of surveillance [12]. Some clinicians feel that there
is an unnecessary number of CT scans with this scheme.
The healthy testis must be closely watched during fol-
low-up, as the long-term risk of developing a contralat-
eral testis cancer after a previous seminoma is about 2-
5%. This usually occurs within the first 6 years and the
risk decreases with time [31]. During clinical examina-
tion, the palpation of the testis must be systematic.
Teaching of auto-palpation techniques is also interesting
and efficient, and should be done whenever possible. In
high-risk patients (fertility problems, testis atrophy, his-
tory of cryptorchidism, contralateral testis microcalcifi-
cations on the ultrasound), an annual doppler
ultrasound exam can be advised to detect early relapse,
and allows conservative treatment [32]. In the mean-
while, risk assessment for recurrence based on rete-testis
involvement and tumor size is the best model until now.
This model has never been validated independently, but
we believe it can help us to assess risk of recurrence in
our daily practice. In the context of potential risks and
benefits of treatment, physicians should consult with the
patient, and family if necessary, to determine the
willingness and ability to adhere to a surveillance pro-
gram. Patients and families should also be informed of
the salvage treatment options and their potential risks.
Radiation therapy
Seminoma cells are extremely radiosensitive, and radia-
tion therapy has been widely used for more than 60
years, and has an excellent long-term track record. This
modality is still a standard management in pure semino-
mas in the United States, and in Europe it is used quite
often [33,34].
Historically, RT was delivered by a cobalt source using
two parallel opposed anterior and posterior treatment
fields, were defined with the help of bony landmarks.
The dose was 30 Gy using 15 fractions. The treated
areas were the para-aortic, homolateral external iliac
nodes and the orchiectomy scar. This technique was
known as the «dog-leg». The fields spread generally up
to the superior aspect of D11 or D10 down to the ingu-
inal ligament. This was the standard method until the
beginning of the 1980’s. Since the 1990’s, following the
low pelvic relapse rates reported in stage I tumors (less
than 5%), the indication for pelvic irradiation was chal-
lenged [10,35,36]. The results of this new approach were
excellent with a low pelvic relapse rate [37-39]. The
reduced volume permits limiting the area, preserving
the remaining testicular function and will hopefully
decrease the secondary cancer rate [40,41]. However
this strategy is still debated [42] in spite of the very well
conducted randomized study by the Medical Research
Council (MRC) Testicular Cancer Working Party. In
this trial 478 patients were randomized between para-
aortic and pelvic RT versus para-aortic RT alone. The
dose was 30 Gy in 15 fractions in both arms. The
relapse rate was 3.4% in the first group, and all recur-
rences were localized above the diaphragm versus 4% in
the second group with 1.6% in the pelvis. Gastrointest-
inal side effects were less important in the second
group. Patients with a scrotal, inguinal or pelvic surgical
history were excluded from the trial [43,44]. A recent
retrospective Australian study contradicts this irradia-
tion option, arguing that despite the proven efficiency of
the irradiation in the patients known to have had cryp-
torchidism, surveillance alone or chemotherapy are still
valid options [44].
Looking for a way to combine those two treatment
options, Thomas et al. have proposed a para-aortic and
common iliac vessel (inferior limit at the acetabulum)
irradiation field. This technique is used at the PMH
[36], and allows the inclusion of most of these possible
relapse regions [37].
However, we note that the irradiation of the para-aor-
tic nodes alone yields good results and that the risk of
nodal relapse exists but is quite low. We find that a
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clinical target volume (CTV) on the right side, compris-
ing the paracaval, precaval and inter aortocaval nodes is
justified. The left side should comprise, additionally, the
latero-aortic, pre-aortic and left renal hilar nodes
[6,7,10,35]. The inguinal orchiectomy scar and ipsilateral
scrotal contents are not treated unless scrotal violation
has occurred during surgery. We propose a planned tar-
get volume (PTV) as the CTV plus a 0.5 cm margin in
all directions.
The optimal RT dose is also still a matter of contro-
versy [45]. Generally, the recommended dose is between
25 and 30 Gy in 15 to 20 fractions. The MRC trial is
the only randomized study that evaluates a dose de-
escalation. It compared a dose of 20 Gy versus 30 Gy
with conventional fractionation in 625 patients. Ten per-
cent of the patients were treated with a « dog-leg » field,
and 90% with para-aortic fields. The relapse rates after a
median follow-up of a little more than five years were
not significantly different. The 20 Gy arm showed a
slightly lower acute toxicity rate (moderate asthenia 5%
vs 20%, work incapacity 28 vs 46%). The only death due
to the primary disease was in the 20 Gy arm [44].
Following this MRC publication, we also use the 20
Gy dose option with a two-week treatment time, which
is now the standard in our institution.
The long term specific survival rate after RT reaches
100% and the disease free survival about 95-97%
[15,43,46,47]. The RT regimen is well tolerated by most
of the patients. The rare deaths in most of the series are
usually due to intercurrent disease. In older studies
where patients received prophylactic mediastinal and
supraclavicular node irradiation, a significant number of
deaths were due to secondary cancers and radiation-
induced cardiac toxicity.
In single or multicenter studies with a sufficient num-
ber of patients, the relapse rates were below 5% and the
relapses within the RT field were rare [19,43,48,49]. In
those cases, a biopsy was needed to avoid missing a dif-
ferent histology, such as a nonseminomatous tumor.
Relapses were located mostly in the mediastinum, the
supraclavicular region and the lungs. The inguinal
region was seldom involved (about 0.5%) and only in
particular cases such as after a prior inguinal surgery
[50]. In many ways, RT was a victim of its own success,
because given the very high cure rates and the fact that
many men were diagnosed with testicular cancer at a
young age (< 30 years), patients lived long enough to
develop late RT toxicities RT [51].
Interest of new radiotherapy techniques
In most of the old seminoma series, treatment was
based on 2D irradiation techniques with cobalt
machines and at higher doses compared to current
recommendations. All this could be the cause of many
short- and long-term complications [24,46,52-54]. The
development of new medical imaging and exploration
techniques has also greatly improved the quality of
treatment. Currently, irradiation is delivered by a high-
energy linear accelerator with a conformational techni-
que, allowing the shaping of the treatment fields to the
expected target volume which was planned with CT-
scan images and 3D reconstruction (RT3D). With the
help of multiple irradiation beams, this technique allows
a better definition of the target volumes and a maximal
sparing of the neighboring critical organs such as kid-
neys, spinal cord..... Computerized dosimetry and dose-
volume histograms are now commonly used [55]. In our
institution, we have treated several cases of seminoma
by Intensity-Modulated Radiation Therapy (IMRT) (Fig-
ure 1). Many institutions tend to use the knowledge
provided by functional imaging, associated with conven-
tional imaging to better define the target volumes. Stu-
dies on the role of PET/CT (positron emission
tomography coupled with a CT-scan) in the determina-
tion of treatment volumes are also under way [56].
Chemotherapy
Cisplatin-based combination CHT is the gold standard
in treating advanced testicular cancer, including both
seminomatous and nonseminomatous tumors. Carbopla-
tin is often preferred because of its better toxicity pro-
file. In a phase II study, Oliver et al. were the first to
describe the use of carboplatin in stage I seminomas.
Seventy-eight patients were included (53 with two
cycles, 25 with one), and after a 44-month median fol-
low-up, only one relapse was observed [57]. In 2005,
Figure 1 Axial view showing planning target volume and
isodose distribution using TomoTherapy, sparing kidneys and
spinal cord in the case of stage I seminoma.
Boujelbene et al. Radiation Oncology 2011, 6:90
http://www.ro-journal.com/content/6/1/90
Page 5 of 12
Oliver et al. reported the results of a multicenter rando-
mized study. The latter included 1477 patients, and
compared adjuvant para-aortic RT (para-aortic strip or
dog-leg field and 20 or 30 Gy depending on the center)
versus a single-cycle carboplatin CHT (area under curve
(AUC) of 7 mg/ml/min) (Table 2) [58]. This non-infer-
iority trial showed a comparable 3-year disease-free sur-
vival time between both arms (94.8 vs 95.9%; p = 0.32)
[58]. These results were still comparable after a 6.5
years follow-up [18]. As a general rule, both treatments
were well tolerated but with different toxicity profiles.
With a little less asthenia, acute toxicity was somewhat
less severe in the CHT arm. Long-term toxicity profiles
are however, not yet available [58]. Only one seminoma-
related death was recorded in the radiotherapy arm.
Interestingly, there were significantly less contralateral
germinal cell tumors in the CHT arm (p = 0.003).
Among relapses, there was more para-aortic (74 vs 9%)
and pelvic nodal relapse (31 vs 0%) in the para-aortic
RT arm, showing the importance of RT in the preven-
tion of those relapses [18,58]. One criticism about this
study was that it was designed to exclude a 3% relapse
risk in the carboplatin arm - it achieved an exclusion
power of only 3.6% (95% confidence interval), the main
goal consequently not being achieved.
There is a slightly increased relapse risk with the sin-
gle-dose carboplatin regimen, as seen in one prospective
study (9% vs 0%) [17]. This was also the case in the
update of the MRC/EORTC (European Organization for
Research and Treatment of Cancer) trial [18].
Generally, the Calvert formula ("Calvert formula total
carboplatin dose (mg) = (target AUC) × (GFR+25)”) is
used to find the optimal dose of carboplatin [59]. The
calculated glomerular filtration rate (GFR) based on
the blood creatinin level is often underestimated. This
can lead to a wrong dose. The MRC/EORTC trial used
a chromium-51 EDTA (Ethylenediaminetetraacetic
acid) radio isotope clearance rate. This product is not
Food and Drug Administration (FDA) authorized yet
but other products exist today such as the iodine-125
iothalamate sodium or more simply the 24 hours
proteinuria.
Current recommendation is to administer either a sin-
gle carboplatin dose (that must be properly dosed with
the help of renal scintigraphy) or two cycles spaced
three weeks apart [34]. Although these recommenda-
tions are not yet supported by randomized studies, sev-
eral phase II studies have evaluated the use of a 2-cycle
carboplatin regimen. These results appear promising but
longer follow-up and a phase III study are still needed.
Although the therapeutic equivalence between carbo-
platin and classic RT is well established, its long-term
effects are still unknown. The sites of relapse after car-
boplatin and surveillance alone are comparable: both are
often isolated and retroperitoneal [60].
In conclusion, the efficiency of the three different
therapeutic options presented here seems to be equiva-
lent. RT series, being the reference treatment, have a
longer track record compared to the two newer options
(Table 3, 4).
Stage II seminoma
Stage II seminoma are usually managed with RT or pla-
tinum-based combination CHT following orchiectomy.
Obviously, surveillance is not an appropriate option for
these men, and therapeutic RPLND has been largely
replaced by CHT and/or RT [7]. No prospective rando-
mized trial has been published to date for the treatment
of stage II seminoma. The optimal treatment depends
on the spread of lymph node invasion.
In old series, a difference between “bulky” and “non-
bulky” disease was often made, but its precise definition
varied between different centers. Mostly bulky disease
was characterized by masses less than 7, most often, 5
Table 2 Relapses and survival in randomized controlled trials in stage 1 seminoma
Reference/No. of
patients
Treatment Total
relapses
No. pelvic
relapses
Relapse-free survival Other
[44]
n = 625
20 Gy RT (n = 313) 11 3 At 2 years: 97% 8/9 pelvic relapses occurred in the PA
RT field group
30 Gy RT (n = 312) 10 6 At 5 years: 97%*
[43]
n = 478
DL RT (n = 242) 9 0 At 3 years: 96.6% At 5
years: 96.2%*
3-years OS: 100%
PA RT (n = 236) 9 4 At 3 years: 96% At 5
years: 96.1%*
3-years OS: 99.3%
[18,58]
n = 1477
RT: PA or DL, 20 or 30
Gy (n = 904)
36 10 At 3 years: 95.9% At 5
years: 96%*
- All pelvic relapses occurred in the PA RT
group
- 74% of relapses in the carboplatin group
occurred in the PA nodes
1 cycle carboplatin
(n = 573)
29 0 At 3 years: 94.8% At 5
years: 94.7%*
RT: radiation therapy; DL: Dog-Leg; PA: para-aortic; OS: overall survival;* data retrieved in update.
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cm in diameter. This corresponds to the latest TNM
classification of N1-N2 and N3 stages (Table 1) [61].
After orchiectomy, the treatment of stage IIA and IIB
seminomas with less than 2.5 cm nodal involvement
(N2 < 2.5 cm) classically consists of RT which remains
to this day the standard treatment [7,33]. These patients
generally respond well to curative RT, and their clinical
outcome is favorable in most cases. The need of che-
motherapy for these patients is still questioned. Plati-
num-based CHT (PEB: cisplatin, etoposide, bleomycin
for 3 cycles or PE: cisplatin, etoposide for 4 cycles, if
there are arguments against bleomycin) were also used
in some centers [7,33]. Prognosis remains good both
with RT and CHT treatment. Five-year survival rates are
about 95-100% [11,62-64].
Patients with more advanced disease with more than
2.5 cm nodes (IB stage with N2 between 2.5 and 5 or
IIC stage) respond better to combined chemotherapy,
despite a greater risk of toxicity compared to RT [65].
In these patients and in patients refusing RT, 3-4 cycles
of PEB or PE CHT represents a valid option depending
of the prognostic group [66]. Unlike stage I disease, a
single agent carboplatin CHT is not proven to be effi-
cient compared to combined cisplatin-based CHT [65].
A retrospective study by Domont et al., showed a sig-
nificantly increased relapse rate after RT, especially with
lymph nodes of more than 3 cm in diameter. Therefore,
CHT plays an important role in stages IIB and beyond
[67].
Ching et al., in a retrospective study including 79
cases, concluded with absence of proof for “prophylac-
tic” left supraclavicular nodal RT; this volume of RT
being of little use in 97% of the patients [68]. Mediast-
inal RT can be toxic for cardiac function, and was aban-
doned after the retrospective studies of Hanks et al. and
Ledermann et al. [53,69]. Chung et al. recommend a
classical infra-diaphragmatic RT including the para-aor-
tic and same side (± contralateral) iliac nodes. Protec-
tion of the contralateral testis is fundamental to
preserve fertility of often young patients. There is no
Table 3 Outcome of patients treated for seminoma from 1999 to 2008 [22]
Stage Treatment Number of
patients
5-Year
relapse rate
(%)
Second
relapse, n
5-Year disease-
specific survival (%)
5-Year overall
survival (%)
Dead of disease/
treatment, n (%)
Death other
cause, n (%)
Surv 313 19.3 3a (1%) 100 99 0 2 (1)
I RT 159 2 0 100 99.3 0 1 (1)
Carb 73 2 0 100 100 0 0
RT 19 8.3 0 100 92.3 0 1 (3)
II CHT 65 4.5 0 100 90.7 3 (5%) 2 (3)
Other 3 0 0 100 100 0 0
III CHT 17 0 0 100 100 0 0
a: After RT for first relapse.
Carb, single-agent carboplatin; CHT, primary combination chemotherapy; Other, other treatment modalities or combination of treatment modalities; RT, radiation;
Surv, surveillance.
Table 4 Advantages and disadvantages of different management options in the treatment of stage I seminoma
Management option Advantage Disadvantage
Surveillance - Excellent cancer cure rate
- No treatment-related toxicity
- Excellent salvage rate
- Avoids overtreatment for most patients
- Frequent follow-up CT, with associated long-
term risks
- Anxiety related to the risk of recurrence
Radiation
therapy
Dog-leg - Excellent cancer cure rate
- No need for routine CT
- Lower recurrence rates compared with patients managed by
surveillance
- Most patients are overtreated
- Second malignancy risk
- Cardiotoxicity
- Fertility impairment
Para-
aortic
- Excellent cancer cure rate
- Lower recurrence rate than patients managed by surveillance
- Frequent follow-up CT, with associated long-
term risks
- Second malignancy risk
- Cardiotoxicity
- Most patients are overtreated
Chemotherapy - Excellent cancer cure rate
- Lower acute toxicity than radiation therapy
- Long-term survival and toxicity unknown
- Frequent follow-up CT, with associated long-
term risks
- Most patients are overtreated
CT: computerised tomography
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proof that to include the contralateral iliac, inguinal, or
scrotal regions in the RT volume is of any benefit. Scro-
tal irradiation was advised in the past in case of undes-
cended testis, previous scrotal or inguinal surgery, or
pT3 and pT4 tumors [11]. The role of the RT-CHT
association is presently being evaluated [70].
In general, we have a longer follow-up with patients
treated with RT than CHT especially with the newer
drugs. Because of this, short term results can overesti-
mate the true effect of the treatment.
In a phase II nonrandomized prospective study, Krege
et al. showed that a monochemotherapy with carbopla-
tin (AUC7) does not allow the full eradication of the
retroperitoneal metastases in stage II seminomas [71].
Gilbert et al., in a letter to the editor, published results
on 81 patients showing the superiority of RT given in
association with carboplatin compared to RT alone [72].
This confirms the results of a previous study by Patter-
son et al. [64].
In stage IIA and IIB seminoma, the RT dose is
between 30-36 Gy, depending on the size of the positive
nodes [7]. The gross tumor volume (GTV) is defined on
the planning CT-scan (computerised tomography). A
first clinical target volume (CTV1) includes the GTV
with a 0.5 cm margin, and a second (CTV2) includes
the lymphatic risk areas (identical to CTV in stage I dis-
ease). We propose that the PTV should comprise both
the CTV1 and CTV2 with a 0.5 cm margin [7,62-64,73].
In stage IIC Seminoma, although local control is possi-
ble with RT, there is a 50% risk of distant metastasis,
and salvage may not be possible in all cases [74]. RT,
therefore, has no major role in this stage of metastatic
seminoma, as BEP combination CHT cures 95% of
patients [75]. In addition, RT to the involved fields after
CHT has not been shown in a retrospective analysis to
add any survival benefit [76]. Today BEP CHT, as in
more advanced stages, remains the standard of care, but
increasing attention has been given to late toxicity of
the treatment, and there is increased interest in further
studies of a single agent CHT [77].
Stage III seminoma
Most of the studies on advanced germinal cancer
include both seminoma and nonseminomatous tumors
[78]. There is no evidence that their chemosensitivity is
any different [79,80]. As there is no bad prognostic sub-
type for advanced pure seminomas, most of the centers
tend to treat them in the same way as the bad prognos-
tic subtypes of nonseminoma. The current standard
treatment consists of 3-4 cycles of BEP or EP CHT
[5,34]. The most recent European consensus evaluates
the risk of complications [11]. The retrospective Dutch
study of Belt-Dusebout et al. establishes the risk of sec-
ondary cancer and cardiovascular complications
following the treatment of testicular cancer in general
and after CHT in particular [81]. Cisplatin dose-intensi-
fied CHT does not seem to be superior to standard BEP
or RT [82]. Post therapeutic follow-up modalities consist
of a four-week post CHT thoraco-abdomino-pelvic CT-
scan [5]. The subsequent management depends on the
size of the residual mass. If the latter is less than 3 cm
in diameter, a simple surveillance in advised. If it is lar-
ger, a PET/CT exam is recommended. If the latter
remains positive, a definitive confirmation by biopsy is
necessary. If the PET/CT is negative, surveillance may
be sufficient [33,83]. In the presence of active residual
tumoral tissue, RT or CHT remains the treatment of
choice [5,33].
Management of relapse
Treatment of relapse depends on different parameters
such as the nature of the initial treatment and the sub-
sequent response, the localization, and the time since
treatment. Most of the stage I seminoma patients who
are under surveillance can be salvaged by RT or cispla-
tin CHT alone. Surgery is not an option [14,21].
In case of relapse after RT, it will almost always be
outside the previous treatment volume. The recom-
mended treatment scheme is a CHT identical to that
used in stage IIC and III, which is efficient in the major-
ity of the patients [7]. Reirradiation is also possible if the
relapse is late, localized, and represent a small volume,
such as a solitary adenopathy. In this case, some groups
recommend pelvic nodal dissection [84]. Our opinion is
that it is by far not the best option in stage I disease
relapse.
In the case of relapse after CHT, and if it occurs less
than three months after one CHT cycle, the disease is
still considered to be sensitive to a platinum-based CHT
salvage treatment [7]. The chemosensitivity persists even
after the second or third CHT cycles [58]. Cisplatin is
the fundamental drug that must be part of any salvage
CHT [77,85]. The most used first line salvage protocols
are the VIP (cisplatin, etoposide, ifosfamide), TIP (pacli-
taxel, ifosfamide, cisplatin) or VeIP (vinblastine, ifosfa-
mide, cisplatin) schedules [84]. In fact, relapse after a
platinum-based CHT is very rare, and about 50% of
them are cured by a salvage CHT [84,86].
Dose-intensification CHT has not been shown to be of
any interest in first or second line salvage treatments
[82]. Post CHT salvage surgery must not be used too
promptly, as a retarded regression of the residual masses
is frequently observed [83,87]. Surgery can possibly be
considered in case of CHT failure, although it is mainly
used in nonseminomatous tumors [88,89].
Up to now, surgery has only been considered only for
residual masses over 3 cm. The use of FDG-PET/CT
(18F-fluorodeoxyglucose positron emission tomography)
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scanning allowed a change in this recommendation [90].
An FDG-PET/CT fixing lesion can be surgically
removed. Even if technically difficult, resection must be
complete.
In patients resistant to CHT, such as those who have
never normalized their markers after a first course of
CHT or who have not responded to salvage CHT, there
is presently no standard treatment. Some authors advise
the use of new drugs such as gemcitabine and paclitaxel.
Dose-intensification CHT is under investigation. The
place of surgery has yet to be defined [91].
bHCG secreting seminoma
bHCG secreting seminoma is a rare form of pure semi-
noma with an incidence of about 10-20% [92]. An
increase in serum bhCG primarily reflects higher tumor
burden but not necessarily a greater metastatic potential
[93]. It has the same clinical and evolutive characteris-
tics as the non-secreting seminoma. Its treatment is
controversial but two studies have been able to deter-
mine that its prognosis is identical to that of the non-
secreting form [94,95]. In stage I, the concentration of
this glycoprotein should return to normal after surgery
[95]. If not, it is strongly suggestive of disease of at least
stage II [94]. In this case, the blood level of bHCG
should be normalized after an adjuvant RT or CHT
treatment [95].
In older series, stage I bHCG secreting seminoma was
considered to carry a worse prognosis [96]. This was
probably due to a selection bias. Even if a bHCG level is
associated with a more important tumor volume, recent
series report a prognosis comparable to the non-secret-
ing forms [94,95,97,98]. The experience in stage II
secreting seminomas is more limited. The treatment is
also generally the same as that for non-secreting semi-
nomas. The prognosis is independent of the bHCG
blood level [92,94,95,99].
Conclusion
Pure seminoma is a rare pathology of the young adult in
whom it is often discovered in the early stages. Its prog-
nosis is generally excellent. Many therapeutic options
are available, especially in stage I tumors. Disease con-
trol and survival rates are similar. To choose the best
therapeutic option, the physician must consider the eco-
nomic impact, the psychological profile of the patient
and future compliance to treatment. All the options
must be presented to the patient, so that he can give his
informed consent. A randomized study comparing the
three therapeutic options is needed from an academic
standpoint knowing its difficult concretization in prac-
tice. Although patients managed with surveillance have
a higher relapse rate, survival is likely equivalent regard-
less of initial management because of excellent salvage
treatment. For advanced stages, the treatment includes
RT, but the mainstay is platinum based CHT: Trials on
combined RT and CHT are under way. bHCG secreting
seminoma is a rare form of pure seminoma, and its
prognosis and treatment is comparable to those of non-
secreting seminoma. In case of relapse, salvage options
depend on previous treatments. Presently, FDG-PET/CT
is an important imaging modality in the therapeutic
decision in case of post CHT residual masses. Dose-
intensification CHT regimens are still being investigated.
Author details
1Department of Radiation Oncology, Centre Hospitalier Universitaire Vaudois
(CHUV), Bugnon 46, CH-1011 Lausanne, Switzerland. 2Department of
Radiation Oncology, Centre Hospitalier Universitaire Habib Bourguiba, 3000
Sfax, Tunisia. 3Department of Pathology, Institut Gustave-Roussy, 94805
Villejuif, France. 4Department of Radiation Oncology, Hôpital de Sion-CHCVs,
CH-1950 Sion, Switzerland. 5Department of Pathology, Hôpital
HabibThameur, 1089 Tunis, Tunisia.
Authors’ contributions
NB, AZ: conception and design. NB drafted the manuscript, AC, NB, KK, SB,
EH, ROM, MO and AZ criticized the manuscript. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 7 April 2011 Accepted: 8 August 2011
Published: 8 August 2011
References
1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin
2010, 60(5):277-300.
2. Levi F, Te VC, Randimbison L, La Vecchia C: Trends in testicular cancer
incidence in Vaud, Switzerland. Eur J Cancer Prev 2003, 12(4):347-9.
3. Khan O, Protheroe A: Testis Cancer. Postgrad Med J 2007, 83(984):624-32.
4. Heidenreich A, Weissbach L, Höltl W, Albers P, Kliesch S, Köhrmann KU,
DIeckmann KP, German Testicular Cancer Study Group: German Testicular
Cancer Study Group. Organ sparing surgery for malignant germ cell
tumor of the testis. J Urol 2001, 166(6):2161-5.
5. Mottet N, Culine S, Iborra F, Avances C, Bastide C, Lesourd A, Michel F,
Rigaud J: Testicular tumors. Prog Urol 2007, 17(6):1035-45.
6. Donohue JP, Zachary JM, Maynard BR: Distribution of nodal metastases in
non seminomatous testis cancer. J Urol 1982, 128:315-20.
7. Schmoll HJ, Jordan K, Huddart R, Pes MP, Horwich A, Fizazi K, Kataja V,
ESMO Guidelines Working Group: Testicular seminoma: ESMO Clinical
Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol
2010, 21(5):140-6.
8. Capelouto CC, Clark PE, Ransil BJ, Loughlin KR: A review of scrotal violation
in testicular cancer: is adjuvant local therapy necessary? J Urol 1995,
153(3 Pt 2):981-5.
9. Pizzocaro G, Nicolai N, Salvioni R: Evolution of the management of stage I
nonseminomatous germ-cell tumors of the testis. World J Urol 1994,
12(3):113-9.
10. Kiricuta IC, Sauer J, Bohndorf W: Omission of the pelvic irradiation in
Stage I testicular seminoma: A study of postorchiectomy paraaortic
radiotherapy. Int J Radiat Oncol Biol Phys 1996, 35(2):293-8.
11. Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M,
Bodrogi I, Bokemeyer C, Cavallin-Ståhl E, Classen J, Clemm C, Cohn-
Cedermark G, Culine S, Daugaard G, De Mulder PH, De Santis M, de Wit M,
de Wit R, Derigs HG, Dieckmann KP, Dieing A, Droz JP, Fenner M, Fizazi K,
Flechon A, Fosså SD, del Muro XG, Gauler T, Geczi L, et al: European
consensus conference on diagnosis and treatment of germ cell cancer:
a report of the second meeting of the European Germ Cell Cancer
Consensus group (EGCCCG): part I. Eur Urol 2008, 53(3):478-96.
Boujelbene et al. Radiation Oncology 2011, 6:90
http://www.ro-journal.com/content/6/1/90
Page 9 of 12
12. Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Gospodarowicz M, von
der Maase H: Prognostic factors for relapse in stage I seminoma
managed by surveillance: a pooled analysis. J Clin Oncol 2002,
20(22):4448-52.
13. Bobba VS, Mittal BB, Hoover SV, Kepka A: Classical and anaplastic
seminoma: difference in survival. Radiology 1988, 167(3):849-52.
14. Warde P, Gospodarowicz MK, Banerjee D, Panzarella T, Sugar L, Catton CN,
Sturgeon JF, Moore M, Jewett MA: Prognostic factors for relapse in stage I
testicular seminoma treated with surveillance. J Urol 1997, 157(5):1705-9.
15. Warde P, Gospodarowicz MK, Panzarella T, Catton CN, Sturgeon JF,
Moore M, Goodman P, Jewett MA: Stage I testicular seminoma: results of
adjuvant irradiation and surveillance. J Clin Oncol 1995, 13(9):2255-62.
16. Kamba T, Kamoto T, Okubo K, Teramukai S, Kakehi Y, Matsuda T, Ogawa O:
Outcome of different post-orchiectomy management for stage I
seminoma: Japanese multi-institutional study including 425 patients. Int
J Urol 2010, 17(12):980-7.
17. Dieckmann KP, Brüggeboes B, Pichlmeier U, Küster J, Müllerleile U, Bartels H:
Adjuvant treatment of clinical stage I seminoma: is a single course of
carboplatin sufficient? Urology 2000, 55(1):102-6.
18. Oliver RT, Mead GM, Fogarty PJ, Stenning SP, MRC TE19 and EORTC 30982
trial collaborators: Radiotherapy versus carboplatin for stage I seminoma:
Updated analysis of the MRC/EORTC randomized trial (abstract). Proc Am
Soc Clin Oncol 2008, 26, 1 (Part II, 1006s).
19. Warde PR, Chung P, Sturgeon J, Panzarella T, Giuliani M, Tew-George B,
Jewett M, Bayley A, Moore M, Catton C, Gospodarowicz M: Should
surveillance be considered the standard of care in stage I seminoma? J:
Clin. Oncol (Meeting Abstracts) 2005, 23:4520.
20. Horwich A, Alsanjari N, A’Hern R, Nicholls J, Dearnaley DP, Fisher C:
Surveillance following orchidectomy for stage I testicular Seminoma. Br J
Cancer 1992, 65(5):775-8.
21. von der Maase H, Specht L, Jacobsen GK, Jakobsen A, Madsen EL,
Pedersen M, Rørth M, Schultz H: Surveillance following orchidectomy for
stage I seminoma of the testis. Eur J Cancer 1993, 29A(14):1931-4.
22. Kollmannsberger C, Tyldesley S, Moore C, Chi KN, Murray N, Daneshmand S,
Black P, Duncan G, Hayes-Lattin B, Nichols C: Evolution in management of
testicular seminoma: population-based outcomes with selective
utilization of active therapies. Ann Oncol 2011, 22(4):808-14.
23. Travis LB, Curtis RE, Storm H, Hall P, Holowaty E, Van Leeuwen FE,
Kohler BA, Pukkala E, Lynch CF, Andersson M, Bergfeldt K, Clarke EA,
Wiklund T, Stoter G, Gospodarowicz M, Sturgeon J, Fraumeni JF Jr, Boice JD
Jr: Risk of second malignant neoplasms among long-term survivors of
testicular cancer. J Natl Cancer Inst 1997, 89(19):1429-39.
24. Travis LB, Fosså SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H, Hall P,
Holowaty E, Andersen A, Pukkala E, Andersson M, Kaijser M,
Gospodarowicz M, Joensuu T, Cohen RJ, Boice JD Jr, Dores GM, Gilbert ES:
Second cancers among 40,576 testicular cancer patients: focus on long-
term survivors. J Natl Cancer Inst 2005, 97(18):1354-65.
25. Powles T, Robinson D, Shamash J, Moller H, Tranter N, Oliver T: The long-
term risks of adjuvant carboplatin treatment for stage I seminoma of
the testis. Ann Oncol 2008, 19(3):443-7.
26. Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J,
Dearnaley DP: Cardiovascular disease as a long-term complication of
treatment for testicular cancer. J Clin Oncol 2003, 21(8):1513-23.
27. Haugnes HS, Aass N, Fosså SD, Dahl O, Klepp O, Wist EA, Wilsgaard T,
Bremnes RM: Predicted cardiovascular mortality and reported
cardiovascular morbidity in testicular cancer survivors. J Cancer Surviv
2008, 2(3):128-37.
28. Mulla MG, Ananthkrishnan G, Mirza MS, Bungay P, Puri S, Chakraborti P:
Renal artery stenosis after radiotherapy for stage I seminoma, a case
report. Clin Oncol (R Coll Radiol) 2007, 19(3):209.
29. Sharda NN, Kinsella TJ, Ritter MA: Adjuvant radiation versus observation: a
cost analysis of alternate management schemes in early-stage testicular
seminoma. J Clin Oncol 1996, 14(11):2933-9.
30. Buchholz TA, Walden TL, Prestidge BR: Cost-effectiveness of posttreatment
surveillance after radiation therapy for early stage seminoma. Cancer
1998, 82(6):1126-33.
31. Fosså SD, Chen J, Schonfeld SJ, et al: Risk of contralateral testicular
cancer: a population-based study of 29,515 U:S: men. J Natl Cancer Inst
2005, 97(14):1056-66.
32. Culine S, Michel F, Rocher L, Mottet N, Davin JL: Comité de Cancérologie
de l’Association Française d’Urologie. Follow-up of testicular germ cell
tumours. Guidelines of the Comité de Cancérologie de l’Association
Française d’Urologie. Prog Urol 2005, 15(4):593-6.
33. Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M,
Bodrogi I, Bokemeyer C, Cavallin-Ståhl E, Classen J, Clemm C, Cohn-
Cedermark G, Culine S, Daugaard G, De Mulder PH, De Santis M, de
Wit M, de Wit R, Derigs HG, Dieckmann KP, Dieing A, Droz JP, Fenner M,
Fizazi K, Flechon A, Fosså SD, del Muro XG, Gauler T, Geczi L, et al:
European consensus conference on diagnosis and treatment of germ
cell cancer: a report of the second meeting of the European Germ
Cell Cancer Consensus group (EGCCCG): part II:. Eur Urol 2008,
53(3):497-513.
34. National Comprehensive Cancer Network clinical practice guidelines in
oncology testicular cancer V:1; 2011. [http://www.nccn.org/professionals/
physician_gls/f_guidelines.asp].
35. Hunter M, Peschel RE: Testicular seminoma. Results of the Yale University
experience, 1964-1984. Cancer 1989, 64(8):1608-11.
36. Thomas GM: Is “optimal” radiation for stage I seminoma yet defined? J
Clin Oncol 1999, 17(9):3004-5.
37. Classen J, Schmidberger H, Meisner C, Winkler C, Dunst J, Souchon R,
Weissbach L, Budach V, Alberti W, Bamberg M, German Testicular cancer
study Group (GTCSG), German Testicular cancer study Group: Para-aortic
irradiation for stage I testicular seminoma: results of a prospective study
in 675 patients. A trial of the German testicular cancer study. Br J Cancer
2004, 90(12):2305-11.
38. Logue JP, Harris MA, Livsey JE, Swindell R, Mobarek N, Read G: Short
course para-aortic radiation for stage I seminoma of the testis. Int J
Radiat Oncol Biol Phys 2003, 57(5):1304-9.
39. Melchior D, Hammer P, Fimmers R, Schüller H, Albers P: Long term results
and morbidity of paraaortic compared with paraaortic and iliac adjuvant
radiation in clinical stage I seminoma. Anticancer Res 2001, 21:2989-93.
40. Zwahlen DR, Martin JM, Millar JL, Schneider U: Effect of radiotherapy
volume and dose on secondary cancer risk in stage I testicular
seminoma. Int J Radiat Oncol Biol Phys 2008, 70(3):853-8.
41. Jacobsen KD, Olsen DR, Fosså K, Fosså SD: External beam abdominal
radiotherapy in patients with seminoma stage I: field type, testicular
dose, and spermatogenesis. Int J Radiat Oncol Biol Phys 1997, 38(1):95-102.
42. Power RE, Kennedy J, Crown J, Fraser I, Thornhill JA: Pelvic recurrence in
stage I seminoma: a new phenomenon that questions modern protocols
for radiotherapy and follow-up. Int J Urol 2005, 12(4):378-82.
43. Fosså SD, Horwich A, Russell JM, Roberts JT, Cullen MH, Hodson NJ,
Jones WG, Yosef H, Duchesne GM, Owen JR, Grosch EJ, Chetiyawardana AD,
Reed NS, Widmer B, Stenning SP: Optimal planning target volume for
stage I testicular seminoma: A Medical Research Council randomized
trial. Medical Research Council Testicular Tumor. J Clin Oncol 1999,
17(4):1146.
44. Jones WG, Fossa SD, Mead GM, Roberts JT, Sokal M, Horwich A,
Stenning SP: Randomized trial of 30 versus 20 Gy in the adjuvant
treatment of stage I Testicular Seminoma: a report on Medical Research
Council Trial TE18, European organisation for the research and
treatment of cancer trial 30942 (ISRCTN18525328). J Clin Oncol 2005,
23(6):1200-8.
45. Milosevic MF, Gospodarowicz M, Warde P: Management of testicular
seminoma. Semin Surg Oncol 1999, 17(4):240-9.
46. Fosså SD, Aass N, Kaalhus O: Radiotherapy for testicular seminoma stage
I: treatment results and long-term post-irradiation morbidity in 365
patients. Int J Radiat Oncol Biol Phys 1989, 16(2):383-8.
47. Oldenburg J, Martin JM, Fosså SD: Late relapses of germ cell malignancies
- incidence, management, and prognosis. J Clin Oncol 2006,
24(35):5503-11.
48. Coleman JM, Coleman RE, Turner AR, Radstone CR, Champion AE: The
management and clinical course of testicular seminoma: 15 years’
experience at a single institution. Clin Oncol (R Coll Radiol) 1998,
10(4):237-41.
49. Santoni R, Barbera F, Bertoni F, De Stefani A, Livi L, Paiar F, Scoccianti S,
Magrini SM: Stage I seminoma of the testis: a bi-institutional
retrospective analysis of patients treated with radiation therapy only.
BJU Int 2003, 92(1):47-52.
50. Borge N, Fosså SD, Ous S, Stenwig AE, Lien HH: Late recurrence of
testicular cancer. J Clin Oncol 1988, 6(8):1248-53.
51. Hoffman KE, Chen MH, Punglia RS, Beard CJ, D’Amico AV: Influence of year
of diagnosis, patient age, and sociodemographic status on
Boujelbene et al. Radiation Oncology 2011, 6:90
http://www.ro-journal.com/content/6/1/90
Page 10 of 12
recommending adjuvant radiation treatment for stage I testicular
seminoma. J Clin Oncol 2008, 26(24):3937-42.
52. Fosså SD, Oldenburg J, Dahl AA: Short- and long-term morbidity after
treatment for testicular cancer. BJU Int 2009, 104(9 Pt B):1418-22.
53. Hanks GE, Peters T, Owen J: Seminoma of the testis: Long-term beneficial
and deleterious effects of radiation. Int J Radiat Oncol Biol Phys 1992,
24:913-919.
54. Richiardi L, Scélo G, Boffetta P, Hemminki K, Pukkala E, Olsen JH,
Weiderpass E, Tracey E, Brewster DH, McBride ML, Kliewer EV, Tonita JM,
Pompe-Kirn V, Kee-Seng C, Jonasson JG, Martos C, Brennan P: Second
malignancies among survivors of germ-cell testicular cancer: a pooled
analysis between 13 cancer registries. Int J Cancer 2007, 120(3):623-31.
55. Martin JM, Joon DL, Ng N, Grace M, Gelderen DV, Lawlor M, Wada M,
Joon ML, Quong G, Khoo V: Towards individualised radiotherapy for
Stage I seminoma. Radiother Oncol 2005, 76(3):251-6.
56. Zouhair A, Ozsahin M, Schaffer M, Albrecht S, Camus F, Jichlinski P,
Mirimanoff RO, Bischof Delaloye A, Meuwly JY, Prior JO: Positron Emission
Tomography and Computer Tomography (PET/CT) in Prostate, Bladder,
and Testicular Cancers. Curr Med Chem 2010, 17(23):2492-502.
57. Oliver RT, Edmonds PM, Ong JY, Ostrowski MJ, Jackson AW, Baille-
Johnson H, Williams MV, Wiltshire CR, Mott T, Pratt WR: Pilot studies of 2
and 1 course carboplatin as adjuvant for stage I seminoma: should it be
tested in a randomized trial against radiotherapy? Int J Radiat Oncol Biol
Phys 1994, 29(1):3-8.
58. Oliver RT, Mason MD, Mead GM, von der Maase H, Rustin GJ, Joffe JK, de
Wit R, Aass N, Graham JD, Coleman R, Kirk SJ, Stenning SP, MRC TE19
collaborators and the EORTC 30982 collaborators: Radiotherapy versus
single-dose carboplatin in adjuvant treatment of stage I seminoma: a
randomised trial. Lancet 2005, 366(9482):293-300.
59. Calvert AH, Egorin MJ: Carboplatin dosing formulae: gender bias and the
use of creatinine-based methodologies. Eur J Cancer 2002, 38(1):11-6.
60. Mead GM, Fossa SD, Oliver RT, Fogarty PJ, Pollock P, Stenning SP: Relapse
patterns in 2,466 stage 1 seminoma patients (pts) entered into Medical
Research Council randomised trials. J Clin Oncol (Meeting Abstracts) 2008,
26:5020.
61. AJCC: Cancer Staging Manual. In Ann Oncol. Volume 21.. 6 edition. Springer
Verlag New York; 2010:(5):140-6.
62. Schmidberger H, Bamberg M, Meisner C, Classen J, Winkler C, Hartmann M,
Templin R, Wiegel T, Dornoff W, Ross D, Thiel HJ, Martini C, Haase W:
Radiotherapy in stage IIA and IIB testicular seminoma with reduced
portals: a prospective multicenter study. Int J Radiat Oncol Biol Phys 1997,
39(2):321-6.
63. Classen J, Schmidberger H, Meisner C, Souchon R, Sautter-Bihl ML, Sauer R,
Weinknecht S, Köhrmann KU, Bamberg M: Radiotherapy for stages IIA/B
testicular seminoma: final report of a prospective multicenter clinical
trial. J Clin Oncol 2003, 21(6):1101-6.
64. Patterson H, Norman AR, Mitra SS, Nicholls J, Fisher C, Dearnaley DP,
Horwich A, Mason MD, Huddart RA: Combination carboplatin and
radiotherapy in the management of stage II testicular seminoma:
comparison with radiotherapy treatment alone. Radiother Oncol 2001,
59(1):5-11.
65. Arranz Arija JA, García del Muro X, Gumà J, Aparicio J, Salazar R, Saenz A,
Carles J, Sánchez M, Germà-Lluch JR: E400P in advanced seminoma of
good prognosis according to the international germ cell cancer
collaborative group (IGCCCG) classification: the Spanish Germ Cell
Cancer Group experience. Ann Oncol 2001, 12(4):487-91.
66. Einhorn LH, Williams SD, Loehrer PJ, Birch R, Drasga R, Omura G, Greco FA:
Evaluation of optimal duration of chemotherapy in favorable-prognosis
disseminated germ cell tumors: a Southeastern Cancer Study Group
protocol. J Clin Oncol 1989, 7(3):387-91.
67. Domont J, Laplanche A, de Crevoisier R, Theodore C, Wibault P, Fizazi K: A
risk-adapted strategy of radiotherapy and cisplatin-based chemotherapy
in stage II seminoma: results of a 20-year experience (abstract). J Clin
Oncol 2005, 23(16):4571.
68. Chung PW, Warde PR, Panzarella T, Bayley AJ, Catton CN, Milosevic MF,
Jewett MA, Sturgeon JF, Moore M, Gospodarowicz MK: Appropriate
radiation volume for stage IIA/B testicular seminoma. Int J Radiat Oncol
Biol Phys 2003, 56(3):746-8.
69. Lederman GS, Sheldon TA, Chaffey JT, Herman TS, Gelman RS, Coleman CN:
Cardiac disease after mediastinal irradiation for seminoma. Cancer 1987,
60(4):772-6.
70. von der Maase H: Do we have a new standard of treatment for patients
with seminoma stage IIA and stage IIB? Radiother Oncol 2001, 59(1):1-3.
71. Krege S, Boergermann C, Baschek R, Hinke A, Pottek T, Kliesch S,
Dieckmann KP, Albers P, Knutzen B, Weinknecht S, Schmoll HJ, Beyer J,
Ruebben H, German Testicular Cancer Study Group (GTCSG): German
Testicular Cancer Study Group (GTCSG). Single agent carboplatin for CS
IIA/B testicular seminoma. A phase II study of the German Testicular
Cancer Study Group (GTCSG). Ann Oncol 2006, 17(2):276-80.
72. Gilbert DC, Pudney D, Van As N, Dearnaley D, Horwich A, Huddart R: Early
outcomes of treating stage IIA/B seminoma with a single cycle of
carboplatin and radiotherapy (abstract). J Clin Oncol 2009, 27(12):2101-2.
73. Jacobsen GK, Mellemgaard A, Engelholm SA, Moller H: Increased incidence
of sarcoma in patients treated for testicular seminoma. Eur J Cancer 1993,
29A:664-8.
74. Warde P, Gospodarowicz M, Panzarella T, Catton C, Sturgeon J, Moore M,
Jewett M: Management of stage II seminoma. J Clin Oncol 1998,
16(1):290-4.
75. Fosså SD, Oliver RT, Stenning SP, Horwich A, Wilkinson P, Read G,
Mead GM, Roberts JT, Rustin G, Cullen MH, Kaye SB, Harland SJ, Cook P:
Prognostic factors for patients with advanced seminoma treated with
platinum-based chemotherapy. Eur J Cancer 1997, 33(9):1380-7.
76. Duchesne GM, Stenning SP, Aass N, Mead GM, Fosså SD, Oliver RT,
Horwich A, Read G, Roberts IT, Rustin G, Cullen MH, Kaye SB, Harland SJ,
Cook PA: Radiotherapy after chemotherapy for metastatic seminoma–a
diminishing role. MRC Testicular Tumour Working Party. Eur J Cancer
1997, 33(6):829-35.
77. Bokemeyer C, Kollmannsberger C, Stenning S, Hartmann JT, Horwich A,
Clemm C, Gerl A, Meisner C, Rückerl CP, Schmoll HJ, Kanz L, Oliver T:
Metastatic seminoma treated with either single agent carboplatin or
cisplatin-based combination chemotherapy: a pooled analysis of two
randomised trials. Br J Cancer 2004, 91(4):683-7.
78. Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ:
Randomized comparison of cisplatin and etoposide and either
bleomycin or ifosfamide in treatment of advanced disseminated germ
cell tumors: an Eastern Cooperative Oncology Group, Southwest
Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol
1998, 16(4):1287-93.
79. Gholam D, Fizazi K, Terrier-Lacombe MJ, Jan P, Culine S, Theodore C:
Advanced seminoma-treatment results and prognostic factors for
survival after first-line, cisplatin-based chemotherapy and for patients
with recurrent disease: a single-institution experience in 145 patients.
Cancer 2003, 98(4):745-52.
80. Mencel PJ, Motzer RJ, Mazumdar M, Vlamis V, Bajorin DF, Bosl GJ:
Advanced seminoma: treatment results, survival, and prognostic factors
in 142 patients. J Clin Oncol 1994, 12(1):120-6.
81. van den Belt-Dusebout AW, de Wit R, Gietema JA, Horenblas S,
Louwman MW, Ribot JG, Hoekstra HJ, Ouwens GM, Aleman BM, van
Leeuwen FE: Treatment-specific risks of second malignancies and
cardiovascular disease in 5-year survivors of testicular cancer. J Clin
Oncol 2007, 25(28):4370-8.
82. Giannis M, Aristotelis B, Vassiliki K, Ioannis A, Konstantinos S, Nikolaos A,
Georgios P, Georgios P, Pantelis P, Meletios-Athanasios D: Cisplatin-based
chemotherapy for advanced seminoma: report of 52 cases treated in
two institutions. J Cancer Res Clin Oncol 2009, 135(11):1495-500.
83. Flechon A, Bompas E, Biron P, Droz JP: Management of post-
chemotherapy residual masses in advanced seminoma. J Urol 2002,
168(5):1975-9.
84. Miller KD, Loehrer PJ, Gonin R, Einhorn LH: Salvage chemotherapy with
vinblastine, ifosfamide, and cisplatin in recurrent seminoma. J Clin Oncol
1997, 15(4):1427-31.
85. Culine S, Abs L, Terrier-Lacombe MJ, Théodore C, Wibault P, Droz JP:
Cisplatin-based chemotherapy in advanced seminoma: the Institut
Gustave Roussy experience. Eur J Cancer 1998, 34(3):353-8.
86. Vuky J, Tickoo SK, Sheinfeld J, Bacik J, Amsterdam A, Mazumdar M, Reuter V,
Bajorin DF, Bosl GJ, Motzer RJ: Salvage chemotherapy for patients with
advanced pure seminoma. J Clin Oncol 2002, 20(1):297-301.
87. Puc HS, Heelan R, Mazumdar M, Herr H, Scheinfeld J, Vlamis V, Bajorin DF,
Bosl GJ, Mencel P, Motzer RJ: Management of residual mass in advanced
seminoma: results and recommendations from the Memorial Sloan-
Kettering Cancer Center. J Clin Oncol 1996, 14(2):454-60.
Boujelbene et al. Radiation Oncology 2011, 6:90
http://www.ro-journal.com/content/6/1/90
Page 11 of 12
88. Motzer RJ, Bosl GJ, Geller NL, Penenberg D, Yagoda A, Golbey R,
Whitmore WF Jr, Fair WR, Sogani P, Herr H: Advanced seminoma: the role
of chemotherapy and adjunctive surgery. Ann Intern Med 1988,
108(4):513-8.
89. Murphy BR, Breeden ES, Donohue JP, Messemer J, Walsh W, Roth BJ,
Einhorn LH: Surgical salvage of chemorefractory germ cell tumors. J Clin
Oncol 1993, 11(2):324-9.
90. De Santis M, Becherer A, Bokemeyer C, Stoiber F, Oechsle K, Sellner F,
Lang A, Kletter K, Dohmen BM, Dittrich C, Pont J: 2-18fluoro-deoxy-D-
glucose positron emission tomography is a reliable predictor for viable
tumor in postchemotherapy seminoma: an update of the prospective
multicentric SEMPET trial. J Clin Oncol 2004, 22(6):1034-9.
91. George DW, Foster RS, Hromas RA, Robertson KA, Vance GH, Ulbright TM,
Gobbett TA, Heiber DJ, Heerema NA, Ramsey HC, Thurston VC, Jung SH,
Shen J, Finch DE, Kelley MR, Einhorn LH: Update on late relapse of germ
cell tumor: a clinical and molecular analysis. J Clin Oncol 2003,
21(1):113-22.
92. Djeffal C, Demailly M, Tillou X, Saint F, Petit J: Place of serum HCG assay in
the follow-up of non-HCG-secreting testicular seminomas. Prog Urol
2008, 18(10):654-6.
93. Hori K, Uematsu K, Yasoshima H, Yamada A, Sakurai K, Ohya M: Testicular
seminoma with human chorionic gonadotropin production. Pathol Int
1997, 47(9):592-9.
94. Mirimanoff RO, Sinzig M, Krüger M, Miralbell R, Thöni A, Ries G, Bosset JF,
Bernier J, Bolla M, Nguyen TD: Prognosis of human chorionic
gonadotropin-producing seminoma treated by postoperative
radiotherapy. Int J Radiat Oncol Biol Phys 1993, 27(1):17-23.
95. Rüther U, Rothe B, Grunert K, Bader H, Sessler R, Nunnensiek C, Rassweiler J,
Lüthgens M, Eisenberger F, Jipp P: Role of human chorionic gonadotropin
in patients with pure seminoma. Eur Urol 1994, 26(2):129-33.
96. Neill M, Warde P, Fleshner N: Management of low-stage testicular
seminoma. Urol Clin North Am 2007, 34(2):127-36.
97. Bruns F, Raub M, Schaefer U, Micke O: No predictive value of beta-hCG in
patients with stage I seminoma-results of a long-term follow-up study
after adjuvant radiotherapy. Anticancer Res 2005, 25(3A):1543-6.
98. Weissbach L, Bussar-Maatz R, Löhrs U, Schubert GE, Mann K, Hartmann M,
Dieckmann KP, Fassbinder J: Prognostic factors in seminomas with special
respect to HCG: results of a prospective multicenter study.Seminoma
Study Group. Eur Urol 1999, 36(6):601-8.
99. Belkacémi Y, Zouhair A, Ozsahin M, Azria D, Mirimanoff RO, Réseau des
Cancers Rares (Rare Cancer Network): Prognostic factors and management
of rare cancers. Cancer Radiother 2006, 10:317-322.
doi:10.1186/1748-717X-6-90
Cite this article as: Boujelbene et al.: Pure seminoma: A review and
update. Radiation Oncology 2011 6:90.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Boujelbene et al. Radiation Oncology 2011, 6:90
http://www.ro-journal.com/content/6/1/90
Page 12 of 12
